HUTCHMED (China) Limited (AIM: HCM)
London
· Delayed Price · Currency is GBP · Price in GBX
222.00
+1.00 (0.45%)
Jan 30, 2025, 11:53 AM GMT+1
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $305.68M USD in the half year ending June 30, 2024, with 51.29% growth. This brings the company's revenue in the last twelve months to $610.81M, down -19.34% year-over-year. In the year 2023, HUTCHMED (China) had annual revenue of $838.00M with 96.52% growth.
Revenue (ttm)
$610.81M
Revenue Growth
-19.34%
P/S Ratio
3.88
Revenue / Employee
$307.25K
Employees
1,988
Market Cap
1.88B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
Oxford Nanopore Technologies | 167.75M |
Genus | 668.80M |
HUTCHMED (China) News
- 18 days ago - HUTCHMED (China) Ltd (HCM) Shares Gap Down to $13.87 on Jan 15 - GuruFocus
- 18 days ago - Hutchmed (HCM) Shares Drop Over 5.7% Amid Delayed Approvals - GuruFocus
- 19 days ago - HUTCHMED (China) Ltd (HCM) Gains Full Approval for ORPATHYS® in China - GuruFocus
- 19 days ago - HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - GlobeNewsWire
- 4 weeks ago - Chinese regulators accept NDA for Orpathys/Tagrisso combo - Seeking Alpha
- 4 weeks ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 4 weeks ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 4 weeks ago - Hutchmed sells stake in unit - BusinessMirror